UK's Mereo BioPharma Q2 loss narrows on lower R&D spending

Mereo BioPharma

11/08/2026 13:28

Overview
UK rare disease drug developer's Q2 net loss narrowed yr/yr due to lower R&D and G&A expenses
Company entered option and license agreement with Sentynl Therapeutics for alvelestat therapy
Cash and cash equivalents fell to $30.1 mln, expected to fund operations into late-2027

Outlook
Company expects cash to fund operations into late-2027, excluding potential alvelestat option payments
Mereo and Ultragenyx expect update on setrusumab regulatory path by year-end 2026
Global Phase 3 trial of alvelestat could begin in early 2027 if Sentynl exercises option

Result Drivers
LOWER R&D SPENDING - Co said R&D expenses fell due to reduced investment in setrusumab and completion of preparatory work for alvelestat
LOWER G&A EXPENSES - Co attributed lower G&A expenses to reduced investment in pre-commercial activities for setrusumab and other cost savings
FOREIGN EXCHANGE IMPACT - Lower net foreign currency translation loss contributed to the narrowed net loss

Company press release: ID:nGNX7ZdvVx

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$7.005 mln
 
Q2 Operating Income
 
-$7.03 mln
 
Q2 Pretax Loss
 
$7.005 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $1.50, about 450.7% above its August 10 closing price of $0.27

Reuters Recommended Reads
Aug 10 - Biohaven Q2 net loss narrows on lower R&D spend
Aug 10 - Fractyl Health Q2 net loss narrows on lower expenses
Aug 10 - Eli Lilly's weight-loss pill secures first European nod in Britain

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)